IE
ACTU

Israel Englander’s Actuate Therapeutics ACTU Stock Holding History

Israel Englander’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$148K Buy
+96,684
New +$224K ﹤0.01% 5395
2025
Q2 		– Sell
-12,185
Closed -$82.5K – 6437
2025
Q1 		$82.5K Buy
+12,185
New +$97.8K ﹤0.01% 5464

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return
AIM
ABS Investment Management Greenwich, Connecticut $159M AUM

Israel Englander's ACTU Position: Q2 2026 in Review

Israel Englander opened a new position in Actuate Therapeutics (ACTU) in Q2 2026: 96,684 shares worth $148K. The stake represents ﹤0.01% of the portfolio and ranks #5395 among its holdings. This is a return to the name: Israel Englander previously reported a position in ACTU as recently as Q1 2025.

Israel Englander first reported a position in ACTU in Q1 2025 and has held it in 2 quarters since. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Israel Englander held 96,684 shares of Actuate Therapeutics worth $148K as of Q2 2026.
  • Actuate Therapeutics was a new Israel Englander position in Q2 2026.
  • Actuate Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #5395 holding.
  • Israel Englander first reported a position in Actuate Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.